UroGen Pharma (URGN) Misses Q3 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Jefferies Assumes UroGen Pharma (URGN) at Buy
November 8, 2018 8:38 AM ESTJefferies analyst Chris Howerton assumes coverage on UroGen Pharma (NASDAQ: URGN) with a Buy rating and a price target of $77.00 (from $73.00).
The analyst assumes primary coverage from analyst Matthew Andrews.
For an analyst ratings summary and ratings history on UroGen... More
